Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

November 30, 2024

Conditions

Glioblastoma Multiforme

Interventions

DRUG

Tinostamustine

infusion given over 60 minutes

Trial Locations (5)

Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona

Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid

South Texas Accelerated Research Therapeutics (START), Madrid

Kantonsspital, Sankt Gallen

University Hospital, Zurich

All Listed Sponsors

lead

Mundipharma Research Limited

INDUSTRY

NCT05432375 - Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Biotech Hunter | Biotech Hunter